aplastic anemia | Page 35 | Aplastic Anemia & MDS International Foundation

aplastic anemia

Etiology and survival of aplastic anemia: a study based on clinical investigation

Author(s): 
Jain D, Kumar R, Tyagi N, Negi A, Pande A, Mahajan A, Pandey PK, Malik R, Raina V, Malik BK
Primary Author: 
Jain D
Journal Title: 
J Clin Lab Anal
Original Publication Date: 
Nov 2012

BACKGROUND:

Management of aplastic anemia is etiology driven, whether constitutional or acquired. Age, gender, and severity of disease also play crucial role in the survival of aplastic anemia. Since, inadequate data are available from India, the present study was conducted with the aim to evaluate the etiology and survival of aplastic anemia.
METHODS:

Three hundred patients were enrolled between May 2007 and April 2010. Severity analysis and chromosomal breakage study was performed and patients were followed up to calculate the survival rate.
RESULTS:

Bone Marrow Diseases: 

Caregivers

Over 65 million Americans take care of other adults, often parents or spouses, or children with special medical needs. Caregivers may be a day-to-day lifeline for patients, or they may support them from afar in otherways. These generous people need support to understand how they can best play their role. 

The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline.

Author(s): 
Leitch HA, Buckstein R, Shamy A, Storring JM
Primary Author: 
Leitch HA
Journal Title: 
Crit Rev Oncol Hematol
Original Publication Date: 
Aug 2012

BACKGROUND:
Myelodysplastic syndromes (MDS) are clonal disorders that result in cytopenias and risk of acute myeloid leukemia. Incidence increases with age and more diagnoses are expected with the aging population. Treatment includes red blood cell transfusion for anemia. The immunomodulatory agents (imids) thalidomide and lenalidomide may induce transfusion independence. This guideline systematically reviews evidence on imids to treat MDS and makes evidence-based recommendations.
METHODS:

The literature and meeting abstracts were searched for phase 2-3 clinical trials. Data on efficacy, toxicity, and which patients benefit were extracted.
RESULTS:

7019 citations on MDS management were identified. Thirteen publications and 9 meeting abstracts met eligibility criteria.
CONCLUSIONS:

Bone Marrow Diseases: 

Late Effects in Hematopoietic Cell Transplant Recipients with Acquired Severe Aplastic Anemia: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research

Author(s): 
Buchbinder D, Nugent DJ, Brazauskas R, Wang Z, Aljurf MD, Cairo MS, Chow R, Duncan C, Eldjerou LK, Gupta V, Hale GA, Halter J, Hayes-Lattin BM, Hsu JW, Jacobsohn DA, Kamble RT, Kasow KA, Lazarus HM, Mehta P, Myers KC, Parsons SK, Passweg JR, Pidala J, Red
Primary Author: 
Buchbinder D
Journal Title: 
Biol Blood Marrow Transplant
Original Publication Date: 
Aug 2012

With improvements in hematopoietic cell transplant (HCT) outcomes for severe

Bone Marrow Diseases: 

Eltrombopag and improved hematopoiesis in refractory aplastic anemia

Author(s): 
Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE
Primary Author: 
Olnes MJ
Journal Title: 
N Engl J Med
Original Publication Date: 
Jul 2012

BACKGROUND:

Severe aplastic anemia, which is characterized by immune-mediated bone marrow hypoplasia and pancytopenia, can be treated effectively with immunosuppressive therapy or allogeneic transplantation. One third of patients have disease that is refractory to immunosuppression, with persistent, severe cytopenia and a profound deficit in hematopoietic stem cells and progenitor cells. Thrombopoietin may increase the number of hematopoietic stem cells and progenitor cells.

METHODS:

Bone Marrow Diseases: